logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
TTRX
Turn Therapeutics Inc.
10.06
1 x 10.04
1 x 10.29
bid
ask
+
0.46
4.79%
12:35 PM
timesize
Ytd155.33%
1y43.71%
9.63
day range
10.17
2.57
52 week range
26.50
Open9.75Prev Close9.60Low9.63High10.17Mkt Cap302.94M
Vol29.99KAvg Vol82.07KEPS-0.19P/E-53.53Forward P/EN/A
BetaN/AShort RatioN/AInst. OwnN/ADividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-1150-d Avg7.67200-d Avg4.801yr Est0.00

TTRX News

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
gurufocus.com
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, n

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
businesswire.com
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b

Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout
marketbeat.com
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout

Turn Therapeutics NASDAQ: TTRX outlined the final stage two design and data-driven expansion of its

Why Is Turn Therapeutics Stock Trading Higher Today?
benzinga.com
Why Is Turn Therapeutics Stock Trading Higher Today?

Turn Therapeutics, Inc. (NASDAQ:TTRX) on Tuesday said a planned interim analysis of its adaptive Pha

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
businesswire.com
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage

Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
businesswire.com
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 De

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
businesswire.com
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b

Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
businesswire.com
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlig

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b

Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
businesswire.com
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b

Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
gurufocus.com
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, l

Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
businesswire.com
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b

Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
businesswire.com
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage b

Turn Therapeutics (NASDAQ:TTRX) Trading 6% Higher – Should You Buy?
defenseworld.net
Turn Therapeutics (NASDAQ:TTRX) Trading 6% Higher – Should You Buy?

Turn Therapeutics Inc. (NASDAQ: TTRX - Get Free Report)'s share price traded up 6% during trading on

Head-To-Head Review: Athersys (NASDAQ:ATHX) versus Turn Therapeutics (NASDAQ:TTRX)
defenseworld.net
Head-To-Head Review: Athersys (NASDAQ:ATHX) versus Turn Therapeutics (NASDAQ:TTRX)

Athersys (NASDAQ: ATHX - Get Free Report) and Turn Therapeutics (NASDAQ: TTRX - Get Free Report) are

Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
businesswire.com
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology

Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
businesswire.com
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group

LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage dermatology c

Reviewing Bio-Path (NASDAQ:BPTH) & Turn Therapeutics (NASDAQ:TTRX)
defenseworld.net
Reviewing Bio-Path (NASDAQ:BPTH) & Turn Therapeutics (NASDAQ:TTRX)

Turn Therapeutics (NASDAQ: TTRX - Get Free Report) and Bio-Path (NASDAQ: BPTH - Get Free Report) are

Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
businesswire.com
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Aff

LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology

Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
businesswire.com
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences

LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology

Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
businesswire.com
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual

LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology

Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarke